Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Show more
Location: Tuborg Boulevard 12, Hellerup, 2900, Denmark | Website: https://ascendispharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
12.58B
52 Wk Range
$118.03 - $229.94
Previous Close
$215.04
Open
$214.35
Volume
693,068
Day Range
$205.52 - $217.00
Enterprise Value
12.89B
Cash
539.1M
Avg Qtr Burn
-26.67M
Insider Ownership
0.76%
Institutional Own.
-
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
YORVIPATH® (palopegteriparatide, developed as TransCon PTH) Details Adult hypoparathyroidism | Approved Quarterly sales | |
SKYTROFA® (Lonapegsomatropin-tcgd) Details Adult growth hormone deficiency | Approved Quarterly sales | |
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
TransCon CNP Details Achondroplasia | PDUFA Approval decision | |
TransCon hGH Details Turner syndrome | Phase 3 Initiation | |
TransCon hGH/TransCon CNP combination Details Achondroplasia | Phase 2 Data readout | |
TransCon IL-2 B/y Details Cancer, Solid tumor/s | Phase 2 Data readout | |
TransCon IL-2 B/y + TLR7/8 Details Solid tumor/s, Cancer | Phase 2 Update | |
TransCon TLR7/8 Agonist +/- pembrolizumab Details Solid tumor/s, Cancer | Phase 2 Update | |
TransCon CNP Details Achondroplasia | Phase 2 Update |
